MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: Strategic Corporate Investment & Corporate Venture Capital (CVC)
Cleveland Clinic Innovations
2022: Cleveland Clinic Ventures: 4 things to know
Cleveland HeartLab
Attachments
Home
Parents
*Architects: BioPharmaceuticals_Inflammation, Allergy & Autoimmune
*Architects: Surgical Technology _ Cardiovascular, Cardiac & Cardiology Companies
*Industry: Ohio
*Portfolio Companies: Cleveland Clinic Innovations
*Portfolio Companies: Excel Venture
2022: Cleveland Clinic Ventures: 4 things to know
Companies: Acquired_(M&A)
Children
2010: Cleveland Clinic researchers get $9.2M grant to continue study of inflammation in heart disease (2010)
2010: Cleveland HeartLab completes $3M funding to expand, develop more inflammation tests (2010)
2010: Demand for this startup’s proprietary test for cardiac inflammation has led to an “explosion” in the company’s business, CEO Jake Orville said 2010
2010: In 2010, the company doubled its number of employees and completed a $3 million fundraise from investors including Glengary and Second Generation Ltd.
2012: Cleveland Heartlab, Inc. Series B $18.4M by OnBioVC (2012)
2012: Poised for more growth, Cleveland HeartLab adds $14.7 million and a new investor (2012)
2017: Cleveland HeartLab to be acquired by Quest Diagnostics
cardiovascular disease (CVD) prevention
Cleveland HeartLab has established a reliable and affordable group of inflammatory biomarkers that offer additive and complimentary insight into a patient's risk for heart disease.
Cleveland HeartLab is a Clinical Reference Laboratory specializing in next-generation cardiovascular disease prevention, diagnosis and management.
In addition to operating a CLIA-certified and CAP-accredited reference laboratory Cleveland HeartLab's proprietary product pipeline includes valuable cardiovascular and inflammatory biomarkers licensed to it exclusively by the Cleveland Clinic
Investment was led by local Cleveland VC firm Mutual Capital Partners Funds, which scored big in August with the $135 million sale of portfolio company OrthoHelix to Minnesota medical device maker Tornier.